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Abstract 
Aim: Combined hepatocellular-cholangiocarcinoma, subtypes with stem-cell features, 
intermediate-cell subtype (INT) shows various histological appearances and may be 
misdiagnosed as intrahepatic cholangiocarcinoma (iCCA). In the present study, we 
aimed to identify specific histological diagnostic markers of INT.  
Methods: We extracted RNA from FFPE sections of 6 INT, 5 iCCA, and 5 hepatocellular 
carcinoma (HCC) cases and compared gene expression between INT, iCCA, and HCC by 
microarray analysis. We then conducted immunohistochemical (IHC) staining of 
potential key molecules identified by microarray analysis, the conventional hepatocytic 
marker, hepatocyte paraffin (HepPar)-1, and the cholangiocytic markers, keratin (K) 7 
and K19, on 35 INT, 25 iCCA, and 60 HCC cases.  
Results: Microarray analysis suggested that malic enzyme 1 (ME1) was significantly 
upregulated in INT. IHC analysis revealed that the positive rates of ME1 in INT, iCCA, 
and HCC were 77.1% (27/35), 28.0% (7/25), and 61.7% (37/60), respectively. Analysis of 
classification and regression trees based on IHC scores indicated that HepPar-1 could 
be a good candidate for discriminating HCC from the others with high sensitivity 
(93.3%) and high specificity (96.7%). A multiple logistic regression model and ROC curve 
analysis based on the IHC scores of ME1, K7, and K19 generated a composite score that 
can discriminate between INT and iCCA. Using this composite score, INT could be 
discriminated from iCCA with high sensitivity (88.6%) and high specificity (88.0%).  
Conclusions: We propose that ME1 is a useful diagnostic marker of INT when used in 
combination with other hepatocytic and cholangiocytic markers. 
 
Key words: combined hepatocellular-cholangiocarcinoma, intermediate cell carcinoma, 
stem cell feature, malic enzyme 1, microarray analysis, immunohistochemical analysis 
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INTRODUCTION 
In the 2010 World Health Organization (WHO) classification 1-3, primary liver 
carcinoma (PLC) is divided into hepatocellular carcinoma (HCC), intrahepatic 
cholangiocarcinoma (iCCA), and combined hepatocellular-cholangiocarcinoma (CHC). 
CHC is relatively rare, comprising < 1% of all PLCs 2. Furthermore, CHC is classified 
into classical type and subtypes with stem-cell features including the typical subtype, 
intermediate-cell subtype, and cholangiolocellular subtype 2. However, it is currently 
known that these “stem-cell” phenotypes may be detected in various forms of PLC, and 
that there is still room for consideration in the current WHO classification 4,5. 
Transitional features from HCC to iCCA and intermediate features between HCC and 
iCCA are often observed in CHC. These findings suggest that CHCs are derived from 
hepatic progenitor cells. Previous studies revealed that hepatic progenitor cells and 
biliary tree stem/progenitor cells do exist in the smallest and most peripheral branches 
of the biliary tree (e.g., the ductules and canals of Hering) and in the peribiliary glands 
of normal bile ducts and in mucosal crypts of the gallbladder, respectively 6,7. 
According to the most recent paper regarding the terminology for PLC 8, the usual 
CHC subtype with stem-cell features, intermediate-cell subtype was redefined as 
“intermediate cell carcinoma (INT)”. The tumor cells of INT may be cuboidal to 
oval-shaped, with pale pink cytoplasm, and may form various structures such as 
strands, trabeculae, and solid nests. Elongated, ill-defined gland-like structure may also 
be present. Usually, mucin production is absent, and marked desmoplastic or acellular 
hyalinized stroma are observed. Even though immunohistochemical stains provide 
supplementary evidence, INT cells express both hepatocytic and cholangiocytic markers 
to various degrees 8,9. Furthermore, INT may be combined with HCC, iCCA, and other 
stem-cell feature subtypes 8. 
Previous studies have revealed that stem-cell features are related to poor prognosis 10, 
 
5 
 
and INT cells showed high proliferation activity 5. These findings suggest that accurate 
identification of the INT component is necessary for its clinical management. Akiba et 
al previously demonstrated that arginase-1 and keratin (K) 8 are useful for the 
pathological diagnosis of INT 11. However, no specific markers of INT have been 
established yet. 
In this study, to identify a specific marker of INT, we examined the gene expression of 
INT by microarray analysis using formalin-fixed paraffin-embedded (FFPE) samples 12, 
and subsequently examined the protein expression of potential key molecules identified 
in the microarray analysis by immunohistochemistry. 
 
MATERIALS AND METHODS 
Microarray analysis 
 For RNA extraction, FFPE blocks from 6 INT cases, 5 iCCA cases, and 5 HCC cases 
were used. All these tumors consisted only of single histological component, i.e. “pure 
type”. Two serial sections of 7 µm thickness were obtained from FFPE blocks using a 
Leica RM2245 microtome (Leica Microsystem K.K., Tokyo, Japan), with an RNase-free 
water-treated blade. For each sample, one section was stained with hematoxylin and 
eosin (HE) whereas another section was used for extracting RNA. Referencing the 
previous mentioned HE-stain section, proper regions of cancerous and non-cancerous 
tissue were identified and separately scraped using blade treated with RNAase-free 
water.  
For microarray analysis using Affymetrix GeneChip® Human X3P Array (Affymetrix, 
Santa Clara, CA, USA), RNA from each sample was isolated, amplified, hybridized and 
labeled in accordance with manufacturer’s instructions for Arcturus® Paradise® PLUS 
Reagent System (Life Technologies, Grand Island, NY, USA) and GeneChip® 3′ IVT 
Express Reagent kit (Affymetrix). The extracted RNA was measured using Nanodrop® 
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ND 1000 (Thermo Fisher Scientific, Waltham, MA, USA). The CEL files were processed 
using the affy package of R to obtain signal intensity values by RNA and present/absent 
calls by MAS5 12. 
 
Patients 
In this study, we evaluated surgically resected liver tissues obtained from patients who 
underwent hepatectomy for PLC at Kurume University Hospital between 2000 and 
2015. Relapse cases and cases with preoperative treatments, including both locoregional 
therapies (e.g. radiofrequency ablation and transcatheter arterial embolization) and 
systemic therapies (e.g. chemotherapy and molecular target drugs), were excluded. 
Thus, we found 35 INT cases and 25 pure type iCCA cases, including the 
aforementioned 6 INT cases and 5 iCCA cases that could be evaluated by microarray 
analysis. However, there were over 800 pure type HCC cases between 2000 and 2015, 
and we randomly selected 60 cases from this population using a random number table. 
Among 25 iCCA cases, 6 and 19 cases were diagnosed as well- and 
moderately-differentiated, respectively. Among the 60 HCC cases, 7, 50, and 3 cases 
were diagnosed as well-, moderately-, and poorly-differentiated, respectively. 
 
Histology 
Liver specimens were fixed in 10% buffered formalin, followed by paraffin embedding. 
We cut consecutive 4-µm-thick sections and stained them with HE.   
Pathological diagnosis was performed according to the 2010 WHO classification of 
tumours of the Digestive System 1-3, which provides a detailed description of the 
histological appearance of INT. Representative photomicrographs of INT are shown in 
Figures 1a-c. According to the recent paper by Brunt et al 8, PLC purely comprised of 
“intermediate cells” referred to as INT. They also described that all PLCs have been 
 
7 
 
reported to occur alone or in combination with one another. Therefore, we included the 
INT cases combined other component(s) in this study and defined these cases as 
“combined type”. Although 13 INT cases were combined type (11 cases with HCC, 1 case 
with iCCA and HCC, another 1 case with CHC stem-cell features, typical subtype), the 
INT components were predominant (>50%) in these cases.  
The degree of fibrosis in the noncancerous liver tissue was assessed as follows: F0, no 
fibrosis; F1, fibrous portal expansion; F2, bridging fibrosis; F3, bridging fibrosis with 
lobular distortion (pre-cirrhosis); and F4, liver cirrhosis, according to the New Inuyama 
classification 14. 
 
Immunohistochemical analysis 
We performed immunohistochemical (IHC) analysis on paraffin-embedded sections of 
the aforementioned INT, iCCA, and HCC cases using the following antibodies: Malic 
enzyme 1 (ME1) monoclonal antibody (316, dilution 1:2000, Thermo Fisher Scientific, 
Rockford, USA), hepatocyte paraffin (HepPar)-1 monoclonal antibody (OCH1E5, 1:100, 
Dako, Glostrup, Denmark), K7 monoclonal antibody (OV-TL 12/30, 1:100, Dako), and 
K19 monoclonal antibody (RCK108, 1:50, Dako). IHC was performed using the Ventana 
Benchmark system (Ventana Automated Systems Tucson, Arizona, USA).  
In ME1 staining, the sinusoidal Kupffer cells and macrophages were strongly stained 
but other inflammatory cells were not. In addition, periportal and perivenular 
non-cancerous hepatocytes and portal cholangioles showed weak to moderate staining. 
Therefore, we used sinusoidal Kupffer cells and macrophages as the internal positive 
controls (Figure 1d). Positive controls of other antibodies were defined as follows: 
HepPar-1, normal hepatocytes; K7 and K19, normal biliary epithelial cells. The 
expression of these molecules was mainly observed in the cytoplasm. We defined cells 
with the same intensity as the positive control as “positive cells”.  
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The percentage of positive cells in tumors was scored as follows: score 0, no positive 
cell; score 1, positive cells < 1%; score 2, 1 ≤ positive cells < 10%; score 3, 10 ≤ positive 
cells < 33.3%; score 4, 33.3 ≤ positive cells < 66.7%; and score 5, 66.7% ≤ positive cells. In 
cases of combined type INT as described above, we only evaluated the INT component.  
The histological diagnoses of each tumor were made by three pathologist (YM, JA, and 
HY) thorough careful conference. IHC analyses were evaluated by two pathologists (YM 
and RK) independently, and IHC scores were almost accorded between them. In the 
cases with discordance, the scores were decided thorough discussion. 
 
Statistical analysis  
The microarray analysis results were subjected to statistical analyses using R 
packages 15, and p < 0.01 was regarded as statistically significant. In addition, the 
correlation between gene expression obtained from microarray analysis and 
immunohistochemical score was examined using polyserial correlation. 
The association between clinicopathological parameters and histological diagnosis was 
examined by ANOVA, Fisher’s exact test, and Log rank test depending on the type of 
data.  
Specific ability of ME1, HepPar-1, K7, and K19 to discriminate three groups was 
examined by following statistical procedures. Because of asymmetrical associations 
between disease groups and four biomarkers, classification and regression trees (CART) 
16 were used to partition disease groups. Based on the results of CART, logistic 
regression was employed to further identify specific associations between biomarkers 
and disease groups by constructing composite score of biomarkers. ROC curve analyses 
were also conducted to estimate accuracy of discriminative abilities based on sensitivity 
and specificity of composite score of biomarkers. JMP Pro 13.2.0 and Stata 15 were used 
to evaluate the clinicopathological parameters and IHC results, respectively, and the 
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differences were considered statistically significant at p < 0.05.  
   In principle, p-values obtained from multiple comparisons amongst three groups are 
shown. However, in cases where further comparison between two groups was performed, 
this has been specifically mentioned. 
 
Ethical statement 
This study was approved by the ethical committee of Kurume University (approved No. 
370) and conformed to the 1964 Declaration of Helsinki and its later amendments or 
comparable ethical standards. Clinical samples were collected from patients after 
written informed consent was obtained. 
 
RESULTS 
Microarray analysis 
The expression of 47,000 genes was examined by microarray analysis. We evaluated 
the genes showing significant differences in expression (enhanced or decreased 
expressed) between cancerous tissues and non-cancerous liver tissues in each group. 
Comparison of the 3 groups of these genes revealed that 91 genes showed significantly 
and specifically different expression in INT compared to in iCCA and HCC (Figure 2, 
Table 1). Of the 91 genes, we focused on ME1, which showed the highest expression in 
INT compared to in iCCA and HCC.   
 
Clinicopathological findings 
The clinicopathological findings of each group are summarized in Table 2. The ratio of 
patients infected with hepatitis virus (HCV and/or HBV) was significantly lower in INT 
than in HCC. In the context of fibrosis of the non-cancerous liver tissue, the frequency of 
F4 and F3 was significantly higher in INT than in iCCA (INT 51.4% (18/35), iCCA 4.0% 
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(1/25), and HCC 35.0% (21/60); p<0.0001, overall; p<0.0001, INT vs iCCA). Although 
vascular invasion was more frequently observed in INT and iCCA than in HCC, there 
were no significant differences among the three groups. Five-year-survival rates of INT, 
iCCA, and HCC were 49.5% (SE9.5), 37.9% (SE11.0), and 74.8% (SE6.8), respectively. 
INT showed significantly worse prognosis than HCC (Figure 3). 
 
Immunohistochemical analysis 
  The expression of ME1, HepPar-1, K7, and K19 was observed in the cytoplasm of 
tumor cells. The summary of IHC scores is shown in Table 3. Representative histological 
and IHC findings of each group are shown in Figure 4.  
   Although statistical significance was not reached in cases used for microarray 
analysis (6 cases for INT, 5 cases for HCC, 5 cases for iCCA), ME1 gene expression and 
IHC score for ME1 tended to show a positive correlation (correlation coefficient 0.57, 
p-value 0.069, polyserial correlation). 
   Amongst the INT group, combined type INT (n=13) had a significantly higher ME1 
score compared to the pure type (n=22) (mean score: combined type 2.92 (SD1.1) vs pure 
type 1.86 (SD1.5), p=0.027, Wilcoxon rank-sum test), whereas no significant differences 
were noted in the score of other markers.  
In the present study, there was no statistical difference between ME1 scores and 
prognosis in each group. However, the analysis of INT subgroups (combined / pure type) 
demonstrated a tendency for a poor prognosis for the combined type compared to the 
pure type; 5-year-survival rate: combined type 33.3% (SE1.5), pure type 58.5% (SE1.1), 
no significant difference. 
Analysis using classification and regression trees based on IHC scores revealed that 
when the cut-off value of the HepPar-1 score was set to 2, HCC and the other two groups 
(INT and iCCA) could be discriminated at a sensitivity of 93.3% (95% C.I. 83.80–98.15) 
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and specificity of 96.7% (95% C.I. 88.47–99.59). Next, multiple logistic regression 
models and ROC curve analyses were performed using ME1, K7, and K19 scores to 
differentiate INT and iCCA, and a simplified composite score：1 × (ME1 score) – 1 × (K7 
score) – 1 × (K19 score) was derived. Using this composite score, when the cut-off value 
was set to –4, patients with a score ≥ –4 were diagnosed with INT with a sensitivity of 
88.6% (95% C.I. 73.26–96.80) and specificity of 88.0% (95% C.I. 68.78–97.45).  
 
DISCUSSION 
A detailed morphological observation is strongly recommended during the pathological 
diagnosis of CHC. Both scirrhous type HCC and K-7- or K19-positive HCC can be 
differential diagnosis of INT, however, these tumors mainly have typical HCC cell forms 
and can be differentiated with careful morphological observation. 3,17-19 On the other 
hand, due to wide structural diversities, such as strands and gland-like structures and 
marked desmoplastic stroma, INT may be misdiagnosed as iCCA 8. In the pathological 
diagnosis in CHC, IHC staining is helpful, but not essential. However, well-established 
diagnostic markers would be useful.   
In this study we probed a specific marker of INT using microarray analysis and 
identified ME1. Moreover, we confirmed that ME1 could be a useful marker in the 
pathological diagnosis of INT. 
 Previous reports demonstrated that CHC with stem-cell features including INT 
showed more malignant potential (i.e. worse prognosis and high proliferative activity) 
compared with HCC 5,10, and these findings are similar to the present study. Therefore, 
accurate diagnosis of INT is essential for clinical management. 
Malic enzymes are the tricarboxylic acid cycle-associated metabolic enzymes that 
catalyze the oxidative decarboxylation of malate to generate pyruvate and either NADH 
or NADPH, and are associated with glutamine metabolism and lipogenesis 20-22. In 
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mammalian cells, three isoforms have been identified to date: ME1, cytoplasmic NADP+ 
-dependent isoform; ME2, mitochondrial NADP+ -dependent isoform, and ME3, 
mitochondrial NADP+ -dependent isoform. ME1 and ME2 are the main isoforms in 
human cells 22. In accordance with these findings, ME1 staining was observed in 
cytoplasm in this study. ME1 contributes to maintain the cellular redox balance by 
producing NADPH, which acts as a key factor for both reductive and antioxidative 
systems 23-25. In addition, Yao et al revealed that ME1 enhances pentose phosphate 
pathway, which is another major route for generating cellular NADPH, through direct 
binding and activating 6-phosphogluconate dehydrogenase 26. Recent studies have 
revealed that various human cancers, including HCC, express ME1 27-34. Through these 
metabolic systems, ME1 may contribute to protect cancer cells from reactive oxygen 
species (ROS) which induce cellular damage and may play an important role in the 
survival of cancer cells and treatment-resistance 27-34. Furthermore, it is thought that 
ME1 participate in migratory ability of cancer cells by promoting epithelial 
mesenchymal transition (EMT) 27,28,34. Through these processes, ME1 enhances the 
proliferative activity and invasive ability of tumor cells and correlates with poor 
prognosis. Thus, ME1 seems to be a marker for aggressive biological features.  
In the present study, more than 1% of tumor cells (i.e. score ≥ 2) were positive for ME1 
in 77.1% (27/35) of INTs, whereas in only 24.0% (6/25) of iCCAs. Our scoring formula 
using ME1, K7, and K19 can discriminate between INT and iCCA with a sensitivity and 
specificity of 88.6% and 88.0%, respectively. This finding suggested that ME1 is a useful 
marker for discriminating INT and iCCA in combination with K7 and K19. 
However, more than 1% of the tumor cells were positive for ME1 also in 51.7% (31/60) 
of HCCs. Wen et al reported that all 65 cases of HCCs examined, expressed ME1 and 
53.8% (35/65) of these cases demonstrated high expression of ME1 28. Furthermore, high 
expression of ME1 was associated with poor prognosis in HCC. These results of IHC 
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analysis were similar to our study, however, there was no statistical difference between 
ME1 expression scores and prognosis in any histological type in our study. While the 
exact reason for the differences observed between the studies are not known, technical 
issues and/or differences in assessment could have caused the differences in the results.   
In our study, only 20.0% (7/35) of INTs showed HepPar-1 positive cells (i.e. score ≥ 1). 
Moreover, there was no case with a HepPar-1 score ≥ 4 in INT. Similarly, in a study of 
Akiba et al, which did not take into account the expression intensity of immunostaining, 
as few as 28.1% of INTs were HepPar-1 positive 11 and there are arguably not many 
cases where INTs displayed strong expression of HepPar-1. Our result demonstrated 
that a case with a HepPar-1 score ≥ 2 may be diagnosed as HCC with high sensitivity 
(93.3%) and high specificity (96.7%). Therefore, it is important to evaluate the presence 
of cells showing strong HepPar-1 staining to discriminate between HCC and others 
(INT and iCCA). Consequently, we advocate the diagnostic algorithm of detecting INT 
(Figure 5). 
Recent studies reported that ME1 metabolism is regulated by a mutation of major 
oncogenes or antioncogenes, such as KRAS, myc, or TP53 24,29,31,32,35. Liu et al reported 
that TP53, RYR3, FBN2, CTNNB1, and ARID1A were mutated in CHC 36; however, the 
subtype of CHC was not mentioned. Sasaki et al also reported that CHC including INT 
showed mutation in KRAS, IDH1/2, ARID1A, TERT, and TP53 37. These studies 
suggested that INT upregulates ME1 possibly by mutation of oncogenes, such as KRAS 
and TP53. Further studies of the correlation between oncogenic mutations and ME1 
expression, mutations in the ME1 gene itself, and other factors are needed.     
As a previous report demonstrated 33, it is difficult to evaluate ME1 staining because of 
marked heterogeneities in both the proportion and intensity of the stain. Therefore, it is 
important to define the internal control, as has been done here. In this study, we did not 
evaluate the proportion of cells stained weakly and moderately by each antibody. 
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   In recent years, in addition to conventional poor prognostic factors (tumor diameter, 
portal invasion, clinical stage, etc.), molecular biological prognostic factors have been 
explored in HCC. Egawa et al found that Forkhead box M1 (FoxM1) is an independent 
poor prognostic factor and showed its possible application as a treatment target 38. 
Likewise, several past studies 27-34 indicated the possible applications of ME1 for HCC 
as poor prognostic factor or a treatment target. In our study, however, in terms of both 
HCC and INT, as no associations were found in immunohistochemical scores between 
ME1 and prognosis, this will require further study.  
This study has some limitations. First, this study included only a small number of INT 
samples due to its rarity. Studies using a large cohort should be performed to clarify the 
pathological and molecular characteristics of INT. Second, we included 13 cases of INT 
combined with other component(s); however, in all cases, INT component was 
predominant (>50%). At this moment, there is no clear definition of INT in terms of the 
percentage of INT component in the WHO classification 2. Well-established diagnostic 
criteria are needed. Furthermore, we did not investigate other subtypes of CHC stem 
cell features (i.e. the typical subtype and the cholangiolocellular subtype). It is not 
known if ME1 can help distinguishing these subtypes, and the diagnostic challenge still 
remains. Hence, in future studies, we intend to determine the similarities and/or 
differences between INT and these subtypes. Moreover, other candidate genes, such as 
CPD and DNMT1, detected by microarray analysis are our next research targets. 
In conclusion We propose that ME1 is a potential diagnostic marker of INT in 
combination with other hepatocytic and cholangiocytic markers (HepPar-1, K7, and 
K19). 
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Figure legends 
Figure 1. Histological appearance of INT and positive internal controls of ME1 staining. 
(a-c) Typical structures of INT (HE); cord-like and small solid nests (a. scale bar = 50µm), 
trabeculae, strands and gland-like structures (b. scale bar = 50µm), with marked 
desmoplastic or acellular hyalinizes stroma. The tumor cells are cuboidal to oval-shaped, 
with pale or pink cytoplasm (c. scale bar = 20µm).  
(d) Sinusoidal Kupffer cells (arrows) are strongly stained by ME1 (d. scale bar = 20µm).  
 
Figure 2. Heat map based on microarray analysis. 
First, we evaluated the genes that showed different expression patterns compared with 
the non-cancerous liver tissue in each group (INT, iCCA, and HCC). Subsequently, we 
detected 91 genes that specifically showed a change in expression in INT compared with 
iCCA and HCC. 
 
Figure 3. Overall survival of INT, iCCA, and HCC (Kaplan-Meier analysis). 
Five-year-survival rates were 49.5% (SE9.5), 37.9% (SE11.0), and 74.8% (SE6.8) in INT, 
iCCA, and HCC, respectively. INT shows significantly worse prognosis compared with 
HCC. 
 
Figure 4. Representative IHC findings of INT, iCCA, and HCC (HE and IHC. scale bar = 
50µm). 
INT case showing (a) strong-positive staining of ME1 (d), weakly stained HepPar-1 (g), 
moderately stained K7 (j) and K19 (m). iCCA case showing (b) strong-positive staining 
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of K7 (k) and K19 (n), but negative for ME1 (e) and HepPar-1 (h). HCC case showing (c) 
strong-positive staining of HepPar-1 (i) and heterogenous staining of ME1 (f), but 
negative for K7 (l) and K19 (o). 
 
Figure 5. Proposed algorithm of pathological diagnosis for INT. Composite score can 
discriminate between INT and iCCA with high sensitivity and specificity. *Composite 
score = 1×(ME1 score) – 1×(K7 score) – 1×(K19 score).  
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Figure.4
Figure.5
Table 1:  
Representative significantly different genes in INT compared with iCCA and HCC 
 
Average log2 ratio to the matched non-tumor sample 
  INT iCCA HCC P-value 
Upregulate 
 ME1 3.21 0.46 0.55 0.0019 
 CPD 2.52 0.40 0.17 0.0016 
 DNMT1 2.18 0.30 0.37 0.0019 
 FAM122B 1.84 0.58 0.01 0.0077 
 ARNT2 1.69 0.23 0.21 0.0021 
 PHF12 1.62 0.43 0.37 0.0028 
 RACGAP1 1.54 0.47 0.11  0.0038 
 E2F3 1.52 0.41 0.34 0.0017 
Downregulate     
 MTND2P28///ND2 -1.37 -0.54 0.30 0.0050 
 COX3 -1.34 -0.46 0.39 0.0030 
 CCDC69 -1.29 -0.16 -0.03 0.0023 
 CD52 -1.29 -0.53 -0.21 0.0012 
 
Representative genes that were significantly upregulated or downregulated in INT 
compared with iCCA and HCC are listed in order of magnitude of average log2 ratio to 
the matched non-tumor sample. The p-value indicates differences among all three 
groups obtained by multiple comparisons. 
Abbreviations: ME1, malic enzyme 1; CPD, carboxypeptidase D; DNMT1, DNA 
(cytosine-5-)-methyltransferase 1; FAM122B, family with sequence similarity 122B; 
ARNT2, aryl-hydrocarbon receptor nuclear translocator 2; PHF12, PHD finger protein 
12; RACGAP1, Rac GTPase activating protein 1; E2F3, E2F transcription factor 3; 
MTND2P28///ND2, MT-ND2 pseudogene 28 /// MTND2; COX3, cytochrome c oxidase III; 
CCDC69, coiled-coil domain containing 69; CD52, cluster of differentiation 52. 
  
Table 2: Summary of clinicopathological findings 
 
  INT iCCA HCC P-value 
 Case 35 25 60 
 Age, average ± SD 67.2 ±11.5 63.2 ±12.0 68.5 ±10.7 0.1461 
 Male : female 28 : 7 15 : 10 43 : 17 0.2378 
 Virus infection 17 (48.6%) 10 (40.0%) 43 (71.7%) 0.0094 
 INT vs HCC†    0.0293 
 INT vs iCCA†    0.6024 
 Tumor size, average 40.4 ± 23.2 47.1 ± 19.6 34.9 ± 24.9 0.0895 
  (mm ± SD) 
 Vascular invasion 25 (71.4%) 19 (76.0%) 34 (56.7%) 0.1461 
 Intrahepatic metastasis 6 (17.1%) 6 (24.0%) 10 (16.7%) 0.7236 
 Liver fibrosis (F0/F1,2/F3,4) 2/15/18 12/12/1 1/38/21 <0.0001 
 INT vs HCC†    0.1027 
  INT vs iCCA†    <0.0001 
 
Abbreviations: SD, standard deviation; INT, intermediate cell carcinoma; HCC, 
hepatocellular carcinoma; iCCA, intrahepatic cholangiocarcinoma. “Virus infection” 
means infection of hepatitis C virus and/or hepatitis B virus. 
The p-value indicates differences among all three groups obtained by multiple 
comparisons, except for (†), wherein the p-value was obtained from a comparison 
between two groups.  
 
 
  
Table 3: Summary of immunohistochemistry analysis. 
 
Distribution of positive cells (score: 0/1/2/3/4/5) 
Group INT iCCA HCC P-value 
Case 35 25 60 
 ME1 8/ 0/ 9/ 11/ 7/ 0 18 / 1/ 5/ 1/ 0/ 0 23/ 6/ 11/ 11/ 7/ 2 0.0020 
 HepPar-1 28/ 5/ 1/ 1/ 0/ 0 25/ 0/ 0/ 0/ 0/ 0 3/ 1/ 6/ 20/ 18/ 12 <0.0001 
 K7 14/ 2/ 4/ 7/ 7/ 1 1/ 0/ 1/ 4/ 5/ 14 53/ 4/ 2/ 0/ 1/ 0 <0.0001 
 K19 19/ 3/ 3/ 8/ 2/ 0 1/ 0/ 5/ 4/ 9/ 6 58/ 2/ 0/ 0/ 0/ 0 <0.0001 
 
Abbreviations: INT, intermediate cell carcinoma; iCCA, intrahepatic 
cholangiocarcinoma; HCC, hepatocellular carcinoma; ME1, malic enzyme 1; HepPar-1, 
hepatocyte paraffin-1; K, keratin 
The p-value indicates differences among all three groups obtained by multiple 
comparisons. 
